secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001213900-26-002245
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement
--------------------------------------------------------------------------------

- Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.
- Consulting agreement effective Jan 1, 2026; $800/hr for up to ~40 hours/month.
- Agreement terminates upon consummation of strategic transaction or after 12 months.
- Severance includes annual base salary, target bonus, and medical premiums under prior employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026002245/0001213900-26-002245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026002245/ea0272154-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer